This site is intended for healthcare professionals

EU approves VLA 2001 vaccine for COVID-19.-Valneva SE

Read time: 1 mins
Published:26th Jun 2022

Valneva SE announced that the European Commission has granted marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA 2001, for use as primary vaccination in people from 18 to 50 years of age.

With this approval, VLA 2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe. The marketing authorization will cover all 28 European Union Member States as well as Iceland, Liechtenstein, and Norway.

The EC’s approval follows recommendations yesterday from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to grant marketing authorization. This new marketing authorization in Europe follows conditional marketing authorization in the United Kingdom, which was granted in April 2022, and emergency use authorization granted in the United Arab Emirates and Bahrain in May 2022 and March 2022, respectively.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.